查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细胞和基因治疗製造QC（品管）：欧洲市场分析和预测（2023-2033）
市场调查报告书
商品编码
1432385

细胞和基因治疗製造QC（品管）：欧洲市场分析和预测（2023-2033）

Europe Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 116 Pages | 商品交期: 1-5个工作天内

价格

欧洲细胞和基因治疗製造QC（品管）市场规模预计将从2023年的5.343亿美元成长到2033年的25.456亿美元，预测期内复合年增长率为16.90%。

欧洲细胞和基因治疗製造 QC（品管）市场：简介

主要市场统计数据
预测期 2023-2033
2023年评估 5.343 亿美元
2033年预测 25.456 亿美元
复合年增长率 16.9%

由于核准的治疗方法数量不断增加以及基础设施扩建的需求，欧洲细胞和基因疗法製造 QC（品管）市场预计将扩大。此外，细胞和基因疗法针对的多种疾病需要广泛的製造和品质控制流程，从而促进市场成长。

由于多种因素，欧洲细胞和基因治疗製造品质控制市场正在经历显着成长。随着细胞和基因疗法越来越多地用于治疗各种疾病，对严格的品管措施的需求越来越大，以确保这些先进疗法的安全性、有效性和一致性。欧洲监管机构致力于维持高製造标准，进一步支持市场扩张。此外，分析技术和自动化的进步也增强了品质控制流程并促进高效、可靠的製造。此外，学术机构、生物製药公司和受託製造厂商(CMO) 之间的合作正在促进创新品质控制解决方案的开发。随着欧洲继续在细胞和基因治疗领域发挥主导作用，QC 市场有望持续成长和创新。

本报告调查了欧洲细胞和基因治疗製造 QC（品管）市场，并提供了市场概况、对市场成长的各种影响因素的分析、法律制度、市场规模趋势和预测、各种分类，并总结了详细的分析。主要国家和主要企业的分析。

市场分类

细分 1：依治疗类型

  • 细胞疗法
  • 基因治疗

细分 2：依产品分类

  • 产品
  • 服务

细分 3：按流程

  • 原料准备
  • 上游工程
  • 下游工艺
  • 包装

细分4：按用途

  • 安全测试
  • 效力测试
  • 身份测试
  • 稳定性/遗传保真度测试
  • 其他的

细分 5：依技术分类

  • 聚合酵素链锁反应(PCR)
  • 流式细胞技术
  • 鲎变形细胞裂解物 (LAL)
  • 酵素结合免疫吸附检测法(ELISA)
  • 层析法
  • 质谱
  • 西方印渍术
  • 下一代定序（NGS）
  • 电泳
  • 其他技术

细分 6：按国家/地区划分

  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 其他的

主要参与企业：

  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Lonza.
  • Sartorius AG

目录

执行摘要

第一章 市场

  • 产品定义
  • 市场范围
  • 调查方法
  • 市场概况
    • 全球市场情景
    • 市场足迹和成长潜力
    • 未来性
    • COVID-19 对市场的影响

第二章细胞和基因治疗製造QC（品管）市场：产业分析

  • 法律规范

第三章 欧洲

  • 概述
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 其他地区
    • 按产品类别分類的市场
    • 按治疗类型分類的市场
    • 按流程划分市场
    • 市场由技术决定
    • 按应用分類的市场

第四章 公司简介

  • 製造商
  • 服务
Product Code: BHP1897SS

The Europe Cell and Gene Therapy Manufacturing QC Market Expected to Reach $2,545.6 Million by 2033

Introduction to Europe Cell and Gene Therapy Manufacturing QC Market

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$534.3 Million
2033 Forecast$2,545.6 Million
CAGR16.9%

The Europe cell and gene therapy manufacturing Quality Control (QC) market is expected to reach $2,545.6 million by 2033 from $534.3 million in 2023 at a CAGR of 16.90% during the forecast period 2023-2033. The cell and gene therapy manufacturing quality control (QC) market is projected to grow due to the rising number of approved therapies and the need for expanded infrastructure. Furthermore, the broader range of medical conditions targeted by cell and gene therapies necessitates large-scale manufacturing and QC processes, contributing to market growth.

Market Introduction

The cell and gene therapy manufacturing Quality Control (QC) market in Europe is experiencing notable growth driven by several factors. With the increasing adoption of cell and gene therapies for treating various diseases, there's a rising demand for stringent quality control measures to ensure the safety, efficacy, and consistency of these advanced therapies. European regulatory bodies' emphasis on maintaining high manufacturing standards further propels market expansion. Additionally, advancements in analytical technologies and automation are enhancing QC processes, facilitating efficient and reliable manufacturing. Furthermore, collaborations between academic institutions, biopharmaceutical companies, and contract manufacturing organizations (CMOs) contribute to the development of innovative QC solutions. As Europe continues to play a leading role in the cell and gene therapy landscape, the QC market is poised for continued growth and innovation.

Market Segmentation

Segmentation 1: by Therapy Type

  • Cell Therapy
  • Gene Therapy

Segmentation 2: by Offering

  • Products
  • Services

Segmentation 3: by Process

  • Raw Material Preparation
  • Upstream Processing
  • Downstream Processing
  • Packaging

Segmentation 4: by Application

  • Safety Testing
  • Potency Testing
  • Identity Testing
  • Stability and Genetic Fidelity Testing
  • Others

Segmentation 5: by Technology

  • Polymerase Chain Reaction (PCR)
  • Flow Cytometry
  • Limulus Amebocyte Lysate (LAL)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Chromatography
  • Mass Spectrometry
  • Western Blotting
  • Next-Generation Sequencing (NGS)
  • Electrophoresis
  • Other Technologies

Segmentation 6: by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe cell and gene therapy manufacturing QC market (by offering) has been segmented into products and services. Moreover, the study provides the reader with a detailed understanding of the different applications of cell and gene therapy manufacturing QC in raw material preparation, upstream processing, downstream processing, and packaging.

Growth/Marketing Strategy: Cell and gene therapy manufacturing QC is being used for raw material preparation, upstream processing, downstream processing, and packaging. Various companies are providing products and services to aid in the manufacturing and QC of various cell and gene therapies, which is also the key strategy for market players to excel in the current Europe cell and gene therapy manufacturing QC market.

Competitive Strategy: Key players in the Europe cell and gene therapy manufacturing QC market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe cell and gene therapy manufacturing QC market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Lonza.
  • Sartorius AG

Table of Contents

Executive Summary

1 Markets

  • 1.1 Product Definition
    • 1.1.1 Product Definition
    • 1.1.2 Inclusion and Exclusion Criteria
  • 1.2 Market Scope
    • 1.2.1 Key Questions Answered in the Report
  • 1.3 Research Methodology
    • 1.3.1 Cell and Gene Therapy Manufacturing QC Market
    • 1.3.2 Data Sources
      • 1.3.2.1 Primary Data Sources
      • 1.3.2.2 Secondary Data Sources
    • 1.3.3 Market Estimation Model
    • 1.3.4 Criteria for Company Profiling
  • 1.4 Market Overview
    • 1.4.1 Global Market Scenario
      • 1.4.1.1 Realistic Growth Scenario
      • 1.4.1.2 Optimistic Scenario
      • 1.4.1.3 Pessimistic Scenario
    • 1.4.2 Market Footprint and Growth Potential
    • 1.4.3 Future Potential
    • 1.4.4 COVID-19 Impact on Market
      • 1.4.4.1 Impact on Research and Clinical Operations
      • 1.4.4.2 COVID-19 Impact: Current Scenario of the Market
      • 1.4.4.3 Pre- and Post-COVID-19 Impact Assessment
        • 1.4.4.3.1 Pre-COVID-19 Phase
        • 1.4.4.3.2 Post-COVID-19 Phase

2 Cell and Gene Therapy Manufacturing QC Market: Industry Analysis

  • 2.1 Regulatory Framework
    • 2.1.1 Chemistry, Manufacturing, and Control (CMC) Requirements by the Food and Drug Administration (FDA)
      • 2.1.1.1 Product Testing
      • 2.1.1.2 Microbial Testing
      • 2.1.1.3 Identity
      • 2.1.1.4 Purity
      • 2.1.1.5 Potency
      • 2.1.1.6 Viability
      • 2.1.1.7 Cell Number or Dose
    • 2.1.2 Quality Aspects of Cell and Gene Therapy Products by the European Medicines Agency (EMA)
      • 2.1.2.1 Characterization
      • 2.1.2.2 Identity Testing
      • 2.1.2.3 Purity Testing
    • 2.1.3 Current Good Manufacturing Practice (CGMP) Regulations
      • 2.1.3.1 Europe
    • 2.1.4 Regulatory Framework: Cell and Gene Therapy Manufacturing QC Market

3 Europe

  • 3.1 Overview
  • 3.2 Europe
    • 3.2.1 Europe Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.2.2 Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.2.3 Europe Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.2.4 Europe Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.2.5 Europe Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.3 U.K.
    • 3.3.1 U.K. Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.3.2 U.K. Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.3.3 U.K. Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.3.4 U.K. Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.3.5 U.K. Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.4 Germany
    • 3.4.1 Germany Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.4.2 Germany Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.4.3 Germany Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.4.4 Germany Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.4.5 Germany Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.5 France
    • 3.5.1 France Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.5.2 France Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.5.3 France Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.5.4 France Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.5.5 France Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.6 Italy
    • 3.6.1 Italy Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.6.2 Italy Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.6.3 Italy Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.6.4 Italy Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.6.5 Italy Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.7 Spain
    • 3.7.1 Spain Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.7.2 Spain Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.7.3 Spain Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.7.4 Spain Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.7.5 Spain Cell and Gene Therapy Manufacturing QC Market (by Application)
  • 3.8 Rest-of-Europe
    • 3.8.1 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Offering)
    • 3.8.2 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
    • 3.8.3 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Process)
    • 3.8.4 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Technology)
    • 3.8.5 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Application)

4 Company Profiles

  • 4.1 Overview
  • 4.2 Manufacturers
    • 4.2.1 bioMerieux SA
      • 4.2.1.1 Company Overview
      • 4.2.1.2 Role of bioMerieux SA in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.1.3 Key Competitors
      • 4.2.1.4 Financials
      • 4.2.1.5 Analyst Perspective
    • 4.2.2 F. Hoffmann-La Roche Ltd
      • 4.2.2.1 Company Overview
      • 4.2.2.2 Role of F. Hoffmann-La Roche Ltd in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.2.3 Key Competitors
      • 4.2.2.4 Financials
      • 4.2.2.5 Key Insights about the Financial Health of the Company
      • 4.2.2.6 Analyst Perspective
    • 4.2.3 Lonza.
      • 4.2.3.1 Company Overview
      • 4.2.3.2 Role of Lonza. in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.3.3 Key Competitors
      • 4.2.3.4 Financials
      • 4.2.3.5 Analyst Perspective
    • 4.2.4 Miltenyi Biotec B.V. & Co. KG
      • 4.2.4.1 Company Overview
      • 4.2.4.2 Role of Miltenyi Biotec B.V. & Co. KG in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.4.3 Key Competitors
      • 4.2.4.4 Analyst Perspective
    • 4.2.5 Sartorius AG
      • 4.2.5.1 Company Overview
      • 4.2.5.2 Role of Sartorius AG in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.5.3 Key Competitors
      • 4.2.5.4 Financials
      • 4.2.5.5 Analyst Perspective
  • 4.3 Service
    • 4.3.1 Eurofins Scientific
      • 4.3.1.1 Company Overview
      • 4.3.1.2 Role of Eurofins Scientific in the Cell and Gene Therapy Manufacturing QC Market
      • 4.3.1.3 Key Competitors
      • 4.3.1.4 Financials
      • 4.3.1.5 Analyst Perspective
    • 4.3.2 Merck KGaA
      • 4.3.2.1 Company Overview
      • 4.3.2.2 Role of Merck KGaA in the Cell and Gene Therapy Manufacturing QC Market
      • 4.3.2.3 Key Competitors
      • 4.3.2.4 Financials
      • 4.3.2.5 Analyst Perspective

List of Figures

  • Figure 1: Europe Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
  • Figure 2: Europe Cell and Gene Therapy Manufacturing QC Market, Impact Analysis
  • Figure 3: Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), % Share, 2022 and 2033
  • Figure 4: Europe Cell and Gene Therapy Manufacturing QC Market (by Offering), % Share, 2022 and 2033
  • Figure 5: Europe Cell and Gene Therapy Manufacturing QC Market (by Process), % Share, 2022 and 2033
  • Figure 6: Europe Cell and Gene Therapy Manufacturing QC Market (by Technology), % Share, 2022 and 2033
  • Figure 7: Europe Cell and Gene Therapy Manufacturing QC Market (by Application), % Share, 2022 and 2033
  • Figure 8: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
  • Figure 9: Cell and Gene Therapy Manufacturing QC Market: Research Methodology
  • Figure 10: Primary Research Methodology
  • Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 12: Top-Down Approach (Segment-Wise Analysis)
  • Figure 13: Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Realistic Scenario), $Billion, 2022-2033
  • Figure 14: Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Optimistic Scenario), $Billion, 2022-2033
  • Figure 15: Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Pessimistic Scenario), $Billion, 2022-2033
  • Figure 16: Europe Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
  • Figure 17: Impact of COVID-19 on CGT Developmental Activities
  • Figure 18: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
  • Figure 19: Europe Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 20: Europe Cell and Gene Therapy Manufacturing QC Market (by Country), % Share, 2022-2033
  • Figure 21: Europe Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 22: Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 23: Europe Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 24: Europe Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 25: Europe Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 26: U.K. Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 27: U.K. Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 28: U.K. Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 29: U.K. Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 30: U.K. Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 31: U.K. Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 32: Germany Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 33: Germany Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 34: Germany Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 35: Germany Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 36: Germany Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 37: Germany Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 38: France Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 39: France Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 40: France Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 41: France Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 42: France Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 43: France Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 44: Italy Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 45: Italy Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 46: Italy Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 47: Italy Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 48: Italy Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 49: Italy Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 50: Spain Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 51: Spain Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 52: Spain Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 53: Spain Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 54: Spain Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 55: Spain Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 56: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 57: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 58: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 59: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 60: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 61: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 62: Total Number of Companies Profiled
  • Figure 63: bioMerieux SA: Product Portfolio
  • Figure 64: bioMerieux SA: Overall Financials, $Million, 2020-2022
  • Figure 65: bioMerieux SA: Revenue (by Segment), $Million, 2020-2022
  • Figure 66: bioMerieux SA: Revenue (by Region), $Million, 2020-2022
  • Figure 67: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 68: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
  • Figure 69: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
  • Figure 70: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2020-2022
  • Figure 71: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
  • Figure 72: Lonza.: Product Portfolio
  • Figure 73: Lonza.: Overall Financials, $Million, 2020-2022
  • Figure 74: Lonza.: Revenue (by Segment), $Million, 2021and 2022
  • Figure 75: Miltenyi Biotec B.V. & Co. KG: Product Portfolio
  • Figure 76: Sartorius AG: Product Portfolio
  • Figure 77: Sartorius AG: Overall Financials, $Million, 2020-2022
  • Figure 78: Sartorius AG: Revenue (by Segment), $Million, 2020-2022
  • Figure 79: Sartorius AG: Revenue (by Region), $Million, 2020-2022
  • Figure 80: Eurofins Scientific: Product Portfolio
  • Figure 81: Eurofins Scientific.: Overall Financials, $Million, 2020-2022
  • Figure 82: Eurofins Scientific.: Revenue (by Segment), $Million, 2020-2022
  • Figure 83: Eurofins Scientific.: Revenue (by Region), $Million, 2020-2022
  • Figure 84: Merck KGaA: Product Portfolio
  • Figure 85: Merck KGaA: Overall Financials, $Million, 2020-2022
  • Figure 86: Merck KGaA: Revenue (by Segment), $Million, 2020-2022
  • Figure 87: Merck KGaA: Revenue (by Region), $Million, 2020-2022

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Regulatory Scenario: Cell and Gene Therapy Manufacturing QC Market
  • Table 3: Europe Cell and Gene Therapy Manufacturing QC Market Dynamics, Impact Analysis